Fast, Easy Zika Test Developed

Fast, Easy Zika Test Developed

Fast, Easy Zika Test Developed

After the horrendous impacts of Irma, Harvey and Maria, I spoke with my friend Charles Murray, the Chairman/CEO of Penta 5 USA, about keeping the “Bugs at Bay” and “Toxins out of the Way”

And learned that there is a new fast, easy and cheap “dipstick” test for the Zika and dengue viruses could revolutionize public health response to dangerous tropical germs, a new study reports.

The test accurately diagnoses Zika and dengue and can tell the 2 mosquito-borne viruses apart, an area in which commercially available tests now stumble, said senior researcher Lee Gehrke, a professor with the MIT Institute for Medical Engineering and Science.

“In light of the problems with Zika virus causing microcephaly [a genetic abnormality resulting in a smaller-than-normal head] and other defects in babies born to infected mothers, it’s very important a pregnant woman would know if her fever is caused by Zika virus or dengue virus,” said Mr. Gehrke, who’s also a professor at Harvard Medical School.

The new test resembles a pregnancy test strip, Mr. Gehrke noted. The strip contains antibodies that react to the presence of Zika or dengue virus, and gold nano-particles that respond to the antibody reaction.

To use the test, a medical professional would dip the strip into a tube of either blood serum or whole blood.

“If it is a positive test, then we see a dot or a line on the test that results from seeing the gold nanoparticles that signal the antibodies recognizing the viral protein,” Mr. Gehrke said.

The test can tell Zika from dengue, and also can distinguish among four different strains of dengue, he added.

Zika and dengue both belong to the same viral family, which are called flaviviruses.

“They are 2 closely related viruses spread by the same mosquito,” said co-researcher Kimberly Hamad-Schifferli, an associate professor of engineering with the University of Massachusetts in Boston.

The research team, which also included members from Mount Sinai School of Medicine in New York City, developed the new test because current testing products sometimes cross-react between Zika and dengue, providing a false positive for Zika when the patient actually has the other virus, Gehrke said.

Researchers checked the accuracy of the test by testing blood serum samples taken from people in regions where Zika has hit hardest, including Brazil, Colombia, Guatemala, India, Mexico and Panama. Serious birth defects caused by Zika appeared for the 1st time in the Western Hemisphere in Y 2015 in northern Brazil; then the epidemic swept outward.

“We validated the test in the areas where the virus is found, using human serum from infected patients,” Mr. Gehrke said. “This is not just a test we performed using materials in a laboratory. We actually traveled to the endemic areas.”

The test proved 80 to 90% accurate in detecting Zika and avoiding false positives, Hamad-Schifferli said.

It will take about a year to get the test out on the market in Zika-impacted areas, since the technology is based on existing products like pregnancy tests, Ms. Hamad-Schifferli said.

The test also is expected to be very affordable. Currently, material costs are about $5 per strip, but Gehrke said costs should decline as production gets rolling.

“Our target is under $1 per strip, which we think is reasonable once the antibody production is scaled up,” Mr. Gehrke said. “The gold nanoparticles are already quite inexpensive.”

Infectious disease expert Dr. Amesh Adalja said the new test “will fulfill a great need and be of high value.

“The availability of rapid, sensitive and specific diagnostic tests is crucial for the identification, treatment, and control of infectious disease,” said Adalja, a senior associate with the Johns Hopkins Center for Health Security in Baltimore, MD.

He added, “That a rapid antigen test that meets this criteria is feasible for dengue and Zika — two clinically indistinguishable diseases with different prognoses — is a major step forward.”

This report appears in the journal Science Translational Medicine.

Mosquito populations will be high for several weeks after the recent hurricane that struck the US, Puerto Rico, and US Virgin Isalands, and so the populations of those stricken areas need to protect themselves and their neighborhood against the insects and toxins.

After the horrendous impacts of Irma, Harvey and Maria, I spoke with my friend Charles Murray, the Chairman/CEO of Penta 5 USA, about keeping the “Bugs at Bay” and “Toxins out of the Way” this is what Charles told me.

Charles said the continuing war against insects and mosquitoes has many side consequences all of which effect humans and animals. The chemicals are left on all the surrounding tress and ground and the rains wash this into the lakes and streams and underground waters.

We then eat or use this water for our foods at our own peril.

Notably, the large chemical companies rather than spend money on finding out why these insects and mosquitoes bite humans and tackle the solution this way, prefer to develop stronger toxins without any long term checks to see what it does to humans and animal life.

“Penta 5 USA has taken the decision to offer wellness and environmentally friendly products that harm no one.

“The ANYTIME™ no-bite topical lotions are safe for pregnant woman, children and pets leaving no chemical footprint behind. A revolutionary development to replace harsh chemical spraying methods is outdoor ZONE™ no-bite spatial attractant/confounder/repellant  results in the mosquito no longer seeking blood and thus avoids all diseases she passes on.

“No harm to the mosquito she can still pollinate and leave eggs in lakes and streams etc. For rural areas we have the SECURE™ Yard and Garden insecticide sprays that control insects and eggs,” Charles advises.

So, be keenly aware that these are solutions with no chemical footprint left behind that future generations will have to deal with.

Eat healthy, Be healthy, Live lively

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

You must be logged in to post comments :  
CONNECT WITH